92 related articles for article (PubMed ID: 22313439)
1. Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy.
Priest J; Buikema A; Engel-Nitz NM; Cook CL; Cantrell CR
Popul Health Manag; 2012 Apr; 15(2):101-12. PubMed ID: 22313439
[TBL] [Abstract][Full Text] [Related]
2. Utilization and costs of cardiovascular disease medications in dialysis patients in Medicare Part D.
Frankenfield DL; Weinhandl ED; Powers CA; Howell BL; Herzog CA; St Peter WL
Am J Kidney Dis; 2012 May; 59(5):670-81. PubMed ID: 22206743
[TBL] [Abstract][Full Text] [Related]
3. Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life.
Obi EN; Swindle JP; Turner SJ; Russo PA; Altan A
J Manag Care Spec Pharm; 2016 Dec; 22(12):1446-1456. PubMed ID: 27882835
[TBL] [Abstract][Full Text] [Related]
4. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
5. Quality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costs.
Priest JL; Cantrell CR; Fincham J; Cook CL; Burch SP
Popul Health Manag; 2011 Feb; 14(1):43-54. PubMed ID: 21142926
[TBL] [Abstract][Full Text] [Related]
6. Increasing Medicare part D enrollment in medication therapy management could improve health and lower costs.
Stuart B; Loh FE; Roberto P; Miller LM
Health Aff (Millwood); 2013 Jul; 32(7):1212-20. PubMed ID: 23836736
[TBL] [Abstract][Full Text] [Related]
7. A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes.
Fox D; Ried LD; Klein GE; Myers W; Foli K
J Am Pharm Assoc (2003); 2009; 49(2):192-9. PubMed ID: 19289345
[TBL] [Abstract][Full Text] [Related]
8. Antiparkinson drug use and adherence in medicare part D beneficiaries with Parkinson's disease.
Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown C
Clin Ther; 2013 Oct; 35(10):1513-1525.e1. PubMed ID: 24139423
[TBL] [Abstract][Full Text] [Related]
9. Association of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare population.
Simoni-Wastila L; Wei YJ; Qian J; Zuckerman IH; Stuart B; Shaffer T; Dalal AA; Bryant-Comstock L
Am J Geriatr Pharmacother; 2012 Jun; 10(3):201-10. PubMed ID: 22521808
[TBL] [Abstract][Full Text] [Related]
10. Eligibility for the Medicare buy-in programs, based on a survey of income and program participation simulation.
Rupp K; Sears J
Soc Secur Bull; 2000; 63(3):13-25. PubMed ID: 11439702
[TBL] [Abstract][Full Text] [Related]
11. Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly.
Starner CI; Norman SA; Reynolds RG; Gleason PP
Am J Geriatr Pharmacother; 2009 Feb; 7(1):11-9. PubMed ID: 19281936
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Success Factors of a Medication Adherence Tracker Pilot Program in Improving Part D Medication Adherence Metrics in a Medicare Advantage Plan: Importance of Provider Engagement.
Hong M; Esse T; Vadhariya A; Gallardo E; Fosshat MA; Mamvou J; Bruce L; Serna O; Abughosh S
J Manag Care Spec Pharm; 2020 May; 26(5):662-667. PubMed ID: 32347173
[TBL] [Abstract][Full Text] [Related]
13. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
14. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Curr Med Res Opin; 2009 Sep; 25(9):2303-10. PubMed ID: 19635045
[TBL] [Abstract][Full Text] [Related]
15. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population.
Menzin J; Boulanger L; Marton J; Guadagno L; Dastani H; Dirani R; Phillips A; Shah H
Respir Med; 2008 Sep; 102(9):1248-56. PubMed ID: 18620852
[TBL] [Abstract][Full Text] [Related]
16. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
17. The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products.
Zhang Y; Lave JR; Donohue JM; Fischer MA; Chernew ME; Newhouse JP
Med Care; 2010 May; 48(5):409-17. PubMed ID: 20393360
[TBL] [Abstract][Full Text] [Related]
18. The unintended effects of the Medicare Part D low income subsidy.
Decarolis F
Health Policy; 2015 May; 119(5):597-603. PubMed ID: 25716285
[TBL] [Abstract][Full Text] [Related]
19. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population.
Bhosle MJ; Reardon G; Camacho FT; Anderson RT; Balkrishnan R
Am J Geriatr Pharmacother; 2007 Jun; 5(2):100-11. PubMed ID: 17719512
[TBL] [Abstract][Full Text] [Related]
20. The relationship between the low-income subsidy and cost-related nonadherence to drug therapies in Medicare Part D.
Wei II; Lloyd JT; Shrank WH
J Am Geriatr Soc; 2013 Aug; 61(8):1315-23. PubMed ID: 23889465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
